As of May 29
| +0.10 / +0.30%|
The 16 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 34.00, with a high estimate of 46.00 and a low estimate of 23.00. The median estimate represents a +0.15% increase from the last price of 33.95.
The current consensus among 21 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.